Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19. The Non-randomized, Non-controlled, Pilot, Open, Mono-centric REHSCU Study

NCT04611425 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT04611425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04611425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19. The Non-randomized, Non-controlled, Pilot, Open, Mono-centric REHSCU Study
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2020
Completion date
October 22, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory failure, covid-19, sepsis, shock, stroke, trauma